CD274 and neoplasm: Based on Blueprint phase 1 and Blueprint phase 2 project results, when assays with corresponding platforms and antibodies were compared (Ventana SP142, Ventana SP263, Dako 22C3, Dako 28-8, Dako 73-10), high agreement between assays was seen when PD-L1 expression was assessed on tumour cells, except SP-142 PD-L1 assay, which stained less tumour cells.